CLEARWATER, Fla., May 12, 2010 (GLOBE NEWSWIRE) -- Equinox International (Pink Sheets:BOSM) (the “Company”) has closed its purchase of medical biotechnology from Biostem US L.L.C., a Florida medical technology company, for a controlling interest in stock of the Company. As a result, the Company has changed its name to BIOSTEM U.S. CORPORATION and its stock symbol is now BOSM. “We are excited about the opportunity for growth offered by a transfer of our technology to a public company, and look forward to building extensive business development capabilities,” stated John Satino, the Company’s new CEO. Director and new Chief Medical Officer, Dr. Michael Markou, will oversee Biostem’s medical services staff and also play a key role in the Company’s ongoing research projects.
